Although many treatment modalities and schedules for nonmuscle invasive bladder cancer (NMIBC) exist, all yet prove to have limitations and the search for new therapeutic strategies continues. Among these, the combination of intravesical chemotherapy and microwave-induced local hyperthermia has been investigated and clinically tested during more than 15 years.
Objective
An updated review of intravesical radiofrequency (RF)-induced thermo-chemotherapy effect (RITE) for NMIBC with regard to efficacy, adverse events (AEs) and perspectives.
Evidence Acquisition
An extensive and sensitive search for RF-induced chemo-hyperthermia in Medline, Embase, Cochrane and ClinicalTrials.gov databases was performed. A table of published clinical trials up to 2016 was constructed. No meta-analysis could be performed on the basis of new papers.
Evidence Synthesis
Recurrence was seen 59% less after RITE than after mitomycin C (MMC) alone in adjuvant clinical setting with an overall bladder preservation rate after RITE of 85%. The efficacy was proved to be comparable to that of Bacillus Calmette-Guèrin (BCG), based on a single comparative multicentric study. Due to short follow-up, no conclusions can be drawn about time to recurrence and progression. The AE rate in RITE was higher, although not statistically significant, than MMC alone and similar to that of BCG, albeit different in the type of AE. In almost all studies, no severe AEs are reported.
Conclusions
RITE appears as a promising treatment option for NMIBC, particularly for high-risk patients with recurrent tumors, for those unsuitable for radical cystectomy and when Bacillus Calmette-Guèrin treatment is contraindicated. Further high-level evidence is needed for both reliable and reproducible data on efficacy and adverse events.
BabjukMBöhleABurgerM. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol2016
2.
SylvesterRJvan der MeijdenAPMOosterlinckW. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006493466–475 discussion 475-477.
3.
Fernandez-GomezJMaderoRSolsonaEet al;Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol2011603423–430
RigattiPLevAColomboRCombined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol1991203204–210
6.
ColomboRLevADa PozzoLFFreschiMGallusGRigattiPA new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol19951533 Pt 2959–963
7.
ColomboRDa PozzoLFLevAFreschiMGallusGRigattiPNeoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol199615541227–1232
8.
ColomboRDa PozzoLFLevA. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol19981593783–787
9.
ColomboRBrausiMDa PozzoL. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur Urol200139195–100
10.
ColomboRDa PozzoLFSaloniaA. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol200321234270–4276
11.
GofritONShapiroAPodeD. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology2004633466–471
12.
van der HeijdenAGKiemeneyLAGofritON. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol200446165–71 discussion 71-72.
13.
MoskovitzBMeyerGKravtzovA. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol2005164585–589
14.
NativOWitjesJAHendricksenK. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol200918241313–1317
15.
AyresBEConnorACorbishleyCBaileyMJRadiofrequency hyperthermia and mitomycin C for the management of frail patients with high-risk non-muscle invasive bladder cancer who fail intravesical BCG treatment. BJU Int2010106s18
16.
ColomboRMoschiniM[Role of the combined regimen with local chemotherapy and Mw-induced hyperthermia for non-muscle invasive bladder cancer management. A systematic review]. Urologia2013802112–119
17.
LammersRJMWitjesJAInmanBA. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol201160181–93
18.
MoskovitzBHalachmiSMoskovitzMNativONativO10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol2012881041–1049
19.
VolpeARacioppiMBongiovanniL. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy?Urol Int2012893311–318
20.
MaffezziniMCampodonicoFCanepaGManuputtyEETamagnoSPuntoniMIntravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol2014735925–930
21.
ArendsTJHvan der HeijdenAGWitjesJACombined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol20141923708–713
22.
KissBSchneiderSThalmannGNRothBIs thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?Int J Urol2015222158–162
23.
SooriakumaranPChiocchiaVDuttonS. Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients. Urol Int201696183–90
24.
LüdeckeGSchäferLNativO. 949 Radiofrequency induced hyperthermia chemotherapy (RIHTC) in high-risk non-muscle invasive bladder cancer (NMIBC): multiinstitutional, international outcome analysis of 271 treated patients with a follow-up time of more than 2 years. Eur Urol Suppl2015142e949–e949a
25.
ArendsTJHNativOMaffezziniM. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol20166961046–1052
26.
ColomboRSaloniaADa PozzoLF. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol2003472127–139
27.
ColomboRSaloniaALeibZPavone-MacalusoMEngelsteinDLong-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int20111076912–918
28.
KellyJDHYMN: a trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back. http://discovery.ucl.ac.uk/1499935/.
29.
NairRPaiAKaulA. 1109 Challenging the gold standard: a comparison of long-term disease specific outcomes for high-risk non-muscle invasive bladder cancer treated with mitomycin hyperthermia and radical cystectomy. Eur Urol Suppl2014131e1109
30.
WitjesJAHendricksenKGofritORisiONativOIntravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol2009273319–324
31.
HalachmiSMoskovitzBMaffezziniM. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol.2011293259–264
32.
ParoniRSaloniaALevA. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol2001523273–278
33.
CanepaGCampodonicoF. STamagnoCITen years experience with intravesical thermo-chemotherapy mmc 40 mg for non muscle invasive bladder cancer high/intermediate risk. XXIII Congresso Nazionale AURO, 2016, May22-24 Rome, Italy
34.
YatesDRRouprêtMContemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol2011294415–422
